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neuronal cytoplasm as Lewy bodies, mainly composed of alphasynuclein (alphasyn) and
ubiquitin.Theselectivedegenerationofdopaminergicneuronssuggeststhatdopamine itself
may contribute to the neurodegenerative process in PD.Furthermore, mitochondrial
dysfunctionandoxidativestressconstitutekeypathogeniceventsofthisdisorder.Thus,inthis
reviewwegiveanactualperspectivetoclassicalpathwaysinvolvingthesetwomechanismsof
neurodegeneration, including the roleofdopamine in sporadicand familialPD,aswellas in







for PD, since longterm exposure to these drugs leads to dopamine depletion. Moreover,
amphetamine neurotoxicity involves alphasyn aggregation, mitochondrial dysfunction and









ofdopaminergic neurons in the substantia nigra pars compacta (SN), aswell as withmore
widespread neuronal changes that cause complex and variable motor and nonmotor
symptoms.PDisthesecondmostprevalentneurodegenerativebraindisorder,affecting1to
2%ofthepopulationabove65yearsofageanditsprevalenceincreasestoapproximately4%
in individuals above 85 years of age[1, 2]. The etiopathogenesis of PD is still not fully
understood. Inmost cases the disease is sporadic: amultifactorial, idiopathic disorder that
seemstoarisefromacombinationofenvironmentalexposuresandgeneticsusceptibility.The
remainingcasesaretheresultofgeneticinheritance.Moreover,15to20%ofthepatientswith




energy demand.Investigations into postmortem PD brains, particularly, in the SN, have
consistently demonstrated abnormalities in mitochondrial function and increased levels of
oxidative stress [714]. Furthermore, there is evidence of inflammation through microglia
activation in the SN, even at the time of death. The finding that alphasyn is the major
componentofLBsdirectedstudiesonproteinmetabolismanddefectsinproteindegradation
throughtheubiquitin(Ub)proteasomesystem(UPS)andautophagypathwaysascontributory
factors toPDpathogenesis.Thesecellularpathwaysare interconnected, sincemitochondrial








Clinically, PD has often been characterized by the presence of cardinalmotor signs, namely
resting tremor, rigidity, bradykinesia and postural instability. One of the main features
affecting these patients includes a slowness of initiation of voluntary movement with a
progressive reduction in speedandamplitudeof sequentialmotor tasks [17, 18]. For a long
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time, PD was thought to involve a relatively simple neuropathological process primarily
centered on the loss of dopaminergic neurons in the SN. This results in the loss of
dopaminergic transmission in the striatum, leading to the majority of the classic motor
symptomsofPD.Thediseasebecomesevidentwhenapproximately80%ofstriataldopamine
and50%ofnigralneuronsare lost [2,19,20].However, recentevidence indicates thatnon
motorcharacteristicssuchasautonomicinsufficiency,cognitiveimpairment,olfactorydeficits,
sleep disturbance, depression and psychosis are very common during the course of the
disease. The clinical diagnosis of PD is typically based on the presence of cardinal motor
features, absence of atypical findings suggestive of an alternate diagnosis and response to
Levo3,4dihydroxyphenylalanine(LDOPA)[2,21].
InadditiontolossofdopaminergicneuronsintheSN,PDisneuropathologicallycharacterized
by the presence of Lewy bodies (LBs) and Lewy neurites (LNs) in vulnerable populations of
neurons.Theseareintracytoplasmicinsolubleproteininclusionslocatedineithertheneuronal
cellbodyorneuronalprocesses,respectively.TheprincipalcomponentofLBsandLNsisalpha






dysfunction of mitochondria, increased oxidative stress levels and associated molecular
pathways representing a link between the two forms of PD, as well as the natural ageing
process [6]. Environmental factors were long thought to be the principal cause of PD,
particularly after the influenza pandemic of 1918, when a significant number of individuals
developed postencephalitic parkinsonism. Infectious agents in the environment were then
suspected to be the causal factors [25, 26]. This environmental theory was subsequently
supportedbytheidentificationofNmethyl4phenyl1,2,3,6tetrahydropyridine(MPTP)inthe
early 1980’s, whosemetabolite 1methyl4phenylpyridinium (MPP+) is responsible for the
selectivedegenerationofthenigrostriatalpathways,byinhibitingmitochondrialcomplexIof
the respiratory chain and subsequently increasing oxidative stress levels in dopaminergic
neurons. Moreover, MPP+ was shown to bind vesicular monoamine transporters (VMAT)






similar pathogenic mechanism was suggested for rotenone, a common naturally occurring
botanical pesticide, which also acts as an inhibitor of the mitochondrial respiratory chain
complexIandleadstoafailureofthemitochondrialenergysupplyofthecell.Betarbetandco
workers (2000)showedthatchronic treatmentwithrotenonewassufficient tocausetypical
features of PD, including loss of dopaminergic neurons andappearance ofalphasyn positive
inclusions inrodents[31,32].The involvementofoxidativedamagecausedbymitochondrial
dysfunction after rotenone treatmentwas also demonstrated in in vitromodels, suggesting
specific neuronal death by rotenone [33]. In this regard, a large number of environmental
situations and agents have been identified, including farming and rural life, industrial
chemicals, metals, pesticide exposure,however, no conclusive relations between individual
studies have been found[26, 34, 35]. Factors decreasing the risk of developing PD can also
provide valuable clues to understand its etiology. Evidence that cigarette smoking, caffeine
and tea intakemayreduce the risk for PD development appears clear, but there is still
uncertaintyovertheirexactroleinthedisease[36,37].
Over the last two decades, the scientific view of PD etiology has dramatically changed.
AlthoughmostpatientswithidiopathicorlateonsetPD(90%ofallcases)donotseemtohave
inherited the disease, a positive family history is frequently associated with a high risk of
developing PD. Studies in families with rare Mendelian inheritance (510%), where several
causative genes have been identified, show protein aggregation, abnormal handling of
misfolded proteins by theUPS, together with oxidative stress, mitochondrial dysfunction,
alterations in autophagylysosomal pathways and kinase signalingpathways, suggesting that
allplayamajorroleinthepathogenesisofPD[26].
MoleculargeneticanalysisofPDfamilies in the lastyears, inparticular themappingandthe
subsequent cloning of genes that cause inheritable forms of this disorder, has provided
importantinsightsinthemechanismsunderlyingPDpathology.Particularly,ithasbeenshown
that PD is not a single clinical entity, but rather a heterogeneous group of diseases with
different associated pathologies and a variable spectrum of clinical symptoms and signs.
Furthermore,somefamilialformsincludeatypicalclinicalfeatures,suchasyoungonset,onset
withdystoniaor theearlyoccurrenceofdementiaanddysautonomia.Alternatively,PDmay
result from a combination between genetic predisposition and environmental factors, or,
moreover, from common genetic variants in genes identified inmonogenic forms that have
beenfoundtoconferariskofdevelopingthesporadicdisease.
UnderstandingthemechanismsunderlyingtheinitiationandprogressionofPD,camewiththe





15) or genomewide association studies (GWASs) (PARK1618) [4153]. Mutations within 11
genes of these loci have conclusively been demonstrated to cause familial parkinsonism in
either autosomal dominant or recessive forms [2, 54], including PARK1 and PARK4 [SNCA
(alphasyn)],PARK2(parkin),PARK5[ubiquitinCterminalhydrolaseL1(UCHL1)],PARK6[PTEN
induced putative kinase 1 (PINK1)], PARK7 (DJ1), PARK8 [Leucinerich repeat kinase 2
(LRRK2)], PARK9 [ATPase type 13A2 (ATP13A2]), PARK11 [Grb10interacting GYF protein 2
(GIGYF2)],PARK13[Omi/Htra2 (HTRA2)],PARK14[phospholipaseA2groupVI (PLA2G6)],and
PARK15 [Fboxprotein7 (FBXO7)] [26].Furthermore,commonpolymorphismswithin twoof
thesegenes(SNCAandLRRK2)arenowwellassociatedtoriskfactorsforcommonsporadicPD





involveanumberofpathways inthebrainstemandareasoftheneocortex[18,56,57]. It is
presentlyrecognizedthatearlyneuronallossoccursinotherregionsinvolvedinmotorcontrol
[58,59]and inneuronsof themesocortical system [60].The involvementofotherneuronal
populationstakesplacelaterinPDoronlyincertainclinicalphenotypesandincludesneuronal
lossinthecholinergicbasalforebrain[61],inthehypothalamichypocretinsystem[62,63]and
in the upper brainstem serotonin system [64]. Neuronal loss is very restricted to areas
containing LBs, such as the amygdala, the dorsal motor nucleus of the vagus nerve, locus
coeruleusandtheneocortex[6568].AlthoughthepathologyofPDaffectsasortofneuronal
systems, itdoesnotcausesubstantialbraintissue loss[69,70],sincecell loss isrestrictedto
onlycertainneuronalpopulations,includingtheSN[19].
Various typesof studies suggest thatPD is slow inprogressing through thenervous system,
with restrictedpathologyoccurringbefore thecharacteristic symptoms. In fact, theonsetof
PD is so gradual, that it is frequently difficult to check out a patientwhen the disease first
emerges, and by the time the diagnosis ismade, pathology is likely to bewidespread [18].
Many of the earliest symptoms are commonlymisinterpreted, since some are linked to the
normal aging process; these include depression, rheumatism, loss of elasticity and other
secondary symptoms, namely fatigue, autonomic dysfunction, constipation or sleep
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disturbances, leading to insufficient information tomake a definitive diagnosis. Indeed, the
majorsymptomsassociatedtoPDseemtoappearafterasignificantneuronalcellloss.
Theneuropathological distributionof the insoluble inclusions (LBs) constitutedbymisfolded
alphasyn throughout the brain, has gained importance over time. This is due to the work
developedbyHeikoBraakandcolleagues,whoproposeda theory for theprogressionofPD
[71,72],basedonLBpathologyprogressionthroughcelltocellcontact.Theyexaminedbrains
from patients with confirmed diagnoses of neurodegenerative disorder and made several






symptoms [7173] and to the development of the Braak´s staging concept for PD, which
includes six stages that represent presymptomatic (prior to the motor symptoms) and
symptomaticphases[71].
Instage1,Braaketal.(2004)havesuggestedthatLBpathologyappearsoutsidetheSN.These
initial alphasynimmunoreactive inclusions are found within the olfactory system, causing
autonomicandolfactorydeficits.Instage2,theLBsandLNsaremorewidespreadwithinthe
medullaoblongata, includingmonoaminergicareas.During these first stages, the individuals
do not present any perceptible motor symptoms [73]. Stage 3 is characterized by the
progressionofLewypathologyintothebrainstem.Thealphasynpositivedepositsaretypically
foundinthemidbrainandbasalforebrainandlaterspreadintotheSN.Instage4,celllossinto




cognitive dysfunction becomes evident [20, 72, 7476]. In addition, Braak and colleagues
(2003) proposed that projection neurons with no or limited myelination were particularly


















other reactive species and antioxidant defenses, and it may be related to changes in
mitochondrial function and protein clearance [82]. There is considerable evidence for
involvement of mitochondrial dysfunction in sporadic PD, since multiple genes in which
mutationsorpolymorphismsincreasetheriskofPD,arelinkedtomitochondrialfunction[83].
Moreover,mitochondrialtoxinsweredescribedtoinduceaphenotypesimilartoPD[84].
Analysis of biochemicalmarkers for oxidative damage in tissue samples from patients or in
postmortembrainsprovideddirectevidenceofoxidativestressinPD.Increasedlevelsoflipid
peroxidationwerefoundintheSN,assuggestedbydecreasedlevelsofpolyunsaturatedfatty





posttranslationalmodificationshavebeen identifiedonproteins thatmayaffect thedisease
progression [81].This includes increased levelsofoxidizedproteincarbonyls in theSNofPD
patients [89, 90] and nitration of tyrosine residues within LBs in the PD brain [91, 92].
Increased 3nitrotyrosine(3NT) levels have been also detected following systemic
administrationofthePDinducingtoxinMPTP inbaboons[93]andmice[94].Alongwiththe









Thepresenceofhigh amountsof iron in PD SN[101],which contribute to theproductionof
free radicals via the FentonHaberWeiss reaction,has alsobeenpointedout as a cause for
selectivedegenerationoftheseneurons.Inthisreaction,hydrogenperoxide(H2O2)generated
during normal metabolism, during electron transport in mitochondria, or by pathogenic
mechanisms, can be subsequently converted to the extremely toxic hydroxyl radical (.OH),
whichmayelicitcellulardamage,lipidperoxidationandeventuallyapoptosis[102].
Under normal physiological conditions, excess iron can be sequestrated in ferritin and
neuromelanin, and in this respect neuromelanin has been described to be
neuroprotective[103] Thus, elevated levels of iron observed in the SN of PD patients may





PDobserved inhuman subjects [105,106].Complex I is the largestof theelectron transport
chain (ETC) complexes, consisting of 46 subunits, 7 of which are encoded bymitochondrial
DNA (mtDNA) [107]and themajor siteof superoxideproduction in theETC [108].Complex I
activityandexpressionaredecreasedintheSN[109112]andcortex[113]ofPDpatientstoa
greater extent than would be expected from normal aging [107]. Oxidized, functionally
impaired andmisassembled complex I subunits, have been reported in PD [114].Moreover,
complexIdysfunctionwasreportedinskeletalmuscleandplateletsofPDpatients[112].
SN is also particularly vulnerable totoxic effects caused by nitric oxide(.NO), leading to
neurodegenerationofdopaminergicandcatecholaminergiccells,probablyduetothepresence
ofhighconcentrationsof6hydroxydopamine(6OHDA)inthisstructure,whichreadilyreacts
with .NOgeneratingdopamine semiquinones (describedbelow in this article)and increasing
intramitochondrialandcytosolicperoxynitrite(ONOO)formation[83].Indeed,NOisknownto
readily react with superoxide anions (O2
.) to form the highly toxic ONOO, which induces
cellular damage through protein nitration, lipid peroxidation and DNA fragmentation [115].
Apartfromtherecognized.NOcontrolofcomplexIVactivityandcellrespiration,both.NOand
ONOOhavebeen reportedasdirect inhibitorsof complex I, probablydue toSnitrosylation
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dopamine itselfmay be contributing to the neurodegenerative process [117].Moreover, the
loss of dopaminergic neurons in the SN, leading to the degeneration of the nigrostriatal
pathwayandresultinginthemarkedreductioninstriataldopamine,appearstobecrucialfor
thedevelopmentof the clinical featuresof thedisease, asdemonstratedby the remarkable
response of most of the motor symptoms to the dopamine precursor LDOPA (dopamine
replacement therapy). Thus, dopaminemayplay a role in the selectivedegenerationof this
brainareainPD.Undernormalconditions,dopamineissynthesizedfromtyrosinebytyrosine
hydroxylase(TH),theratelimitingenzymeindopaminebiosynthesis,andaromaticaminoacid
decarboxylase. Once formed, dopamineis safely stored in high millimolar concentrations in
synaptic vesicles following uptake by VMAT2 [118]. Impairment of vesicular storage of
dopamine, which may be due to the presence of alphasyn protofibrils, oxidative stress or
weak base compounds such as methamphetamine(further describedbelow)[119], leads to
increased dopaminelevels in the cytoplasm. Concordantly, alphasyn overexpression was
shownto increasecytosoliccatecholamineconcentration[120].MPP+ interactionwithVMAT
and redistribution of vesicular dopamine to the cytosol also causes intracellular dopamine
oxidation [27]. Under conditions of oxidative stress, dopaminehas the potential to form
reactive metabolites by enzymatic and nonenzymatic mechanisms,that may further
contributetomitochondrialdysfunctionandoxidativedamage,acceleratingdopaminergiccell
death inPD.Dopaminemaybemetabolized intracellularly bymonoamineoxidase (MAO), a
mitochondrialenzymepresent inthecytoplasmicsideoftheoutermitochondrialmembrane
and aldehyde dehydrogenase, producing 3,4dihydroxyphenylacetic acid (DOPAC) and H2O2.
MAO exists in two isoforms,MAOA andMAOB,which have different substrate specificity.
Bothisoformsoxidizedopamine,butinhumansdopamineispreferentiallyoxidizedbyMAOB,
whereasinrodentsitispredominantlyoxidizedbyMAOA[121].
In addition, autoxidation of the catechol ring of dopamineproduces O2
.and H2O2,which
mayreact with transition metal ions, such as iron, via the HaberWeiss/Fenton reactions,
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originating the highly toxic hydroxyl radical •OH. This O2
. may also easily react with .NO,
formingthehighlytoxicONOO.
The autoxidation of dopaminealso originates the electrondeficient dopaminequinones or
semiquinones, whichis facilitated by the presence of transition metal ions
[117].Dopaminequinones readily react with cellular nucleophiles, such as the reduced
sulfhydrylgrouponproteincysteinylresidues,andcovalentlymodifyproteinstructure[117].
These cysteinyl residues are often at the active site of proteins and, thus, covalent
modificationbydopaminequinonesoftenresultsininactivationofproteinfunction,whichmay
result in compromised cell survival. This mechanism may play a role in the degenerative
processinPD[122].Dopaminewasfoundtomodifyproteinsassociatedwiththegeneticforms
ofPD, such as alphasyn[123], parkin [124], LRKK2orUCHL1 [125].Other proteins that are
modified by dopamine oxidation include TH[126], superoxide dismutase 2 (SOD2),
mitochondrial creatine kinase, mitofilin and mitochondrial heatshock protein 70
(mtHSP70)[125].Alphasynwas shown to interactwithdopaminequinones stabilizingalpha
synprotofibrils[127]andpromotingalphasynaggregation;interestingly,thisprocessmayalso
prevent dopaminequinones from producinggreater oxidative damage to dopaminergic
neurons [128]. Excess alphasynalso seems to potentiate the production of ROS by
endogenous dopamineand cell death, involving the formation of soluble alphasyn1433
proteincomplexes[129].Moreover,directbindingandfunctionalcouplingofalphasyntothe




K+effluxandmembranehyperpolarization,whichplaya role in thephysiological functionof
dopamineneurons, controlling dopamine release in the striatum. Dopamineneurons in the
ventral tegmental area (VTA) may be less sensitive to KATP channel activation than SN
neurons, due to increased levels of uncoupler protein 2 (UCP2), which provides partial
constitutive impairment of their respiratory chain, and an intrinsic capacity to buffer
mitochondrialROS[131].
Oxidativedamage isalsoknownto impairubiquitinationanddegradationofproteinsby the
proteasome[132].Dopamineoxidationcontributes toadditionalfactors implicated inPD,such








receptor antagonists, such as memantine [134] and MK801[135138]against MPP+
neurotoxicity.Amantadine,anotherNMDAreceptorantagonist,iscurrentlyusedtotreatPDin
humans[139, for review].Glutamate toxicity, or excitotoxicity, has been pointed out as an
alternative source of oxidative stress in PD [107, 140]. The firing patterns of cortical
glutamatergic projections to the basal ganglia seem to be altered in PD. The glutamatergic
projectionstothesubthalamicnucleusbecomeoveractiveinPDandpharmacologicblockade
of subthalamic neurotransmission (to the SN)has antiparkinsonian symptomatic effects and
may also help to protect the remaining dopamine neurons of the SN from excitotoxic
degeneration[140].
Excitotoxicityis caused by a massive influx of extracellular calcium resulting from the
overactivation of the NmethylDaspartate (NMDA)receptor. Cytoplasmic calcium activates
several calciumdependent enzymes involved in the degradation of proteins, phospholipids,
and nucleic acids, many of which can elicit the generation of endogenous ROS or reactive
nitrosative species (RNS)[16, for review]. Activation of these pathwaysmay lead to necrotic





uptake of calcium,generating free radicals. Thus, mitochondrial dysfunction associated with
the loss of calcium homeostasis and enhanced cellular oxidative stress has long been
recognized to play a major role in cell damage associated with excitotoxicity [16]. Under
normal conditions, calcium taken up by mitochondria can physiologically increase ATP
generationbyactivatingmatrixdehydrogenases[141].However,anincreaseinmitochondrial
calciumcanpromoteROSand .NOgeneration,andpromotethe lossofcytochromecdueto
the mitochondrial permeability transition, which can result in increased mitochondrial ROS
release [142]. Mitochondrial buffering of calcium may be impaired in PD, as suggested by
reduced carbonyl cyanide mchlorophenylhydrazonereleasable calciumin PD cybrids[143].

















54, 149, 150](Figure 1) and 2) wholelocus multiplications, including duplications and
triplications,leadingtoapathogenicoverexpressionofthewildtype(WT)protein.
Human alphasyn was first identified as the precursor protein for the nonamyloid beta









signaling and neuronal plasticity [155].Prior findings are consistent with these roles, with
alphasynappearing tocontrol synaptic vesicle fusionand recycling.Mostdata indicate that
alphasyn inhibits synaptic transmission in an activitydependent manner, as observed in
alphasyndeficientmice,exhibitingacceleratedrecoveryofdopaminereleasewhenpresented
tomultiple stimuli [156]. In addition, alphasyn is also predicted to have specific effects in
dopaminergic neurons, where it may negatively regulate the activity of TH,as well as the
activityofDAT[157].Productsresultingfromtheinteractionbetweendopamineandalphasyn
have beenwidely explored to addresswhether this interactionmay produce toxic forms of
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alphasyn [158]. Dopamineis prone to oxidation and its quinone derivatives react with
proteins,ingeneralviaacovalentmodificationofacysteine(asdescribedabove).Alphasyn,





Fibrillization and aggregation of mutant alphasyn play a central role in neurodegenerative
mechanisms, either due to primary alterations in thepeptide sequence or due to increased
levels of physiological protein, possibly exceeding existing pathways of degradation. An
increaseinproteinsthataredeterminedtobedegradedbytheUPSoranimpairmentofthe
UPS function are contributive factors to proteolytic stress due to accumulation and
aggregationofproteinsincytosol.Howalphasynisdegradedisstillamatterofdebate,butitis
likely that both UPS and the lysosomal degradation pathway intervene in regulating the
steadystatelevelsoftheproteinundernormalphysiologicalconditions.Degradationofalpha
syn by the proteasome [162, 163] and the formation of inclusions in neuronal cells treated
with proteasome inhibitors have been described [164, 165]. On the other hand, the
involvementofautophagyandlysosomeshasalsobeendemonstrated[166169].Evidencehas
been shown formutant, andpossibly excessivenormal alphasyn facilitating its pathological
accumulation by impairing the function of protein degradationprocesses[170173].Cuervo et
al.(2004)[170]identifiedinthealphasynsequence,thepentapeptidemotifrequiredtotarget
cytosolic proteins to lysosomal degradation via chaperonemediated autophagy (CMA). In
cellular models and rodents, alphasyn was shown to interact with lysosomeassociated
membrane protein 2A (LAMP2A), a transmembrane receptor of substrates for lysosomal
degradation, giving evidence to the theory that CMA is involved in its clearance [170,
174].Accordingly, LAMP2A gene silencing slowed the degradation of monomeric and
oligomeric species of alphasyn in primary neurons of the ventral midbrain [174]. CMA,
however,wasnottheonlypathwayforalphasyndegradation.Vogiatzietal.(2008)[174]also
reportedthatclearanceofWTalphasynwasinpartmediatedbymacroautophagy.Thestudy
involved the selective macroautophagy inhibitor 3methyladenine (3MA), which led to a
considerable increase of the steady state levels of alphasyn in PC12 cells and in primary
corticalandventralmidbrainneurons,suggestingthatdysfunctionofthisdegradationprocess
could also contribute to the gradual accumulation of endogenousWT alphasyn in sporadic
PD.Furthermore, oxidative stresslinked to mitochondrial dysfunction may also increase
misfoldedproteins and therefore lead to aggregationof alphasyn and subsequentdeathof
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dopaminergic neurons [175]. Thus, alphasyn aggregation itself may also contribute to
increased oxidative stress levels, leading to a vicious cycle in the cell [176]. Pesticides like




aggregation and consequent death of dopaminergic neurons [176]. Moreover, Dauer and






alphasyn, leading to the deletion of exon5, which resulted in the generation of a 112 aa










was shown that human embryonic kidney cells that overexpress alphasyn, show enhanced
susceptibility to cell death and have lower ATP levels compared to control cells [183]. In
brainstemneuronsofmicethatoverexpresshumanA53Tmutantalphasyn,thereisevidence
ofdegeneratinganddysmorphicmitochondriawithDNAdamage[185].Furthermore,inboth
SHSY5Y neuroblastoma cells and isolated rat mitochondria, alphasyn seems to induce
mitochondrialreleaseofcytochromec,increasedmitochondrialcalciumandNO,andoxidative
modification of mitochondrial components. These findings suggest a pivotal role for
mitochondriainoxidativestressandapoptosisinducedbyalphasyn[186].Inamodelofaging
yeast,functionalmitochondriaarerequiredforalphasyntoxicity[187].
Besides all these facts,it has been recognized that alphasyn is one of the most abundant
components of LBs; alphasyn can aggregate under a variety of post translational
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Mutations in the LRRK2 represent the most common known cause of familial PD and are
inherited in autosomal dominant form, but with a significant variation in penetrance. The
resulting disease phenotype is identical to sporadic PD, except for a slightly lower age at
diagnosis[194],whichhasincreasedtheinterestinthisgene.TheLRRK2geneencodesalarge
multidomainproteinwith 2527 amino acids, the physiological functionofwhich is currently
unknown. However, there are numerous functional domains associated with this protein,
including a leucinerich repeat (LRR)domain, a Ras of complex protein (Roc)GTPasedomain
followedby its associatedCterminal of Roc (COR) domain, a kinase domain of the tyrosine
kinaselike (TKL) subfamily, homologous to other mitogenactivated protein kinase kinase
kinase(MAPKKK),andaCterminalWD40domain[195](Figure2).Thiscombinationofmotifs
is highly conserved in vertebrates [196], however, LRRK2 is unusual, since it encodes two
distinct enzymes, kinase and GTPase in the same molecule. Initial biochemical studies on
LRRK2 suggested that this protein is able toundergophosphorylation and tophosphorylate





The single most common mutation occurring in LRRK2, G2019S, is present in the kinase
domainoftheproteinandaugmentsthekinaseactivity[200].Thismutationisresponsiblefor
bothfamilial(4%worldwide)andapparentlysporadic(1%worldwide)PDcases,andhasavery
low frequency in healthy populations (<0.1% worldwide) [194, 205207]. Particularly, most
patients with the G2019S mutation exhibitedalphasynpositive LBs as in sporadic PD [206,
208,209].Tongetal.(2010)[210],showedthataccumulationandaggregationofalphasynand
ubiquitinated proteins occurred in aged LRRK2 germline deletion mice with great loss of
LRRK2.Theautophagylysosomalpathwaywasimpairedtogetherwithanincreaseinapoptotic
celldeath,inflammatoryresponseandoxidativestress.
Although LRRK2 is mainly localized to the cytoplasm, approximately 10% of the protein is




Furthermore, impaired mitochondrial function and an increased susceptibility to apoptosis
wereobservedinexvivomodelsoffibroblastsfromPDpatientscarryingtheG2019Smutation




These studies support an involvement of LRRK2 in mitochondrial dysfunction and impaired
protein degradation pathways with alphasyn accumulation and speculate on the kinase
activityoftheprotein,whichseemstoberequiredforcellulartoxicityandneuronaldeath.
AutosomalRecessiveFormsofPD
Most recessive alleles result in the absenceof the encodedproteinor inactiveprotein, and
consequently to a loss of function.Homozygousor heterozygousmutations in the recessive
genesparkin (PARK2),PTENinducedputativekinase1(PINK1) (PARK6)andDJ1 (PARK7)are
unequivocallyassociatedwithheritable,earlyageatonset,inmostcasesbeforeage40andno
atypical signs [213215].Furthermore, autosomal recessive PD is characterized by: 1) slowly









(UBL) domain followed by three RING finger domains (RING 02) and separated by an in
betweenring (IBR) domain localized at the Cterminal part. Like other RING finger proteins,
parkinactsasanUbE3ligase.IthasanimportantroleinthefunctionofUb,whichisprimarily




to synaptic vesicles, theGolgi complex, endoplasmic reticulum and themitochondrial outer
membrane [223227].Many PDlinked pointmutations alterWT parkin cellular localization,
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solubility or propensity to aggregate [228230]. Other mutations, including insertions or
deletions, lead to parkin lossoffunction, specifically loss of its ligase activity, resulting in
accumulationoftoxicsubstratesanddegeneration[220].However,themostpossiblyrelevant
activity of parkin is related to its neuroprotective function against a variety of pathogenic




regulation of transcription and replication of mtDNA in proliferating cells, stimulating this
organelle’sbiogenesis–aneffectblockedbyparkinshortinterferingRNA(siRNA)knockdown
[231]. Furthermore, in aknockout mouse line for parkin, reduced number of mitochondrial
oxidative phosphorylation proteins, decreased mitochondrial respiratory capacity, age
dependent increased oxidative damage and increased protein and lipid peroxidation were
reported [232], leading to nigrostriatal damage. Changes in mitochondrial morphologyhave
beenalsoobserved,butthisledonlytodisruptionofcomplexIfunctioninnigralmitochondria
and did not result in cell death [233]. Thus, mitochondrial defects and an increased
susceptibility to oxygen radical damage were also reported in a parkin knockout model of
Drosophila,suggestingthatabnormalitiesinparkinubiquitinationfunctionmightbesecondary
in thecourseofpathogenicevents [234,235]. Invitro studiesofPARK2knockdownSHSY5Y
neuroblastomacelllineshowedapoptoticcelldeathandhighlevelsofautoxidizedformsofL
DOPA and dopamine, suggesting that parkin might have important antioxidant properties
[236]. Rothfuss and coworkers[237]confirmed that the association between parkin and





PINK1gene (PARK6)mutations are the secondmost commoncauseof autosomal recessive,
earlyonset parkinsonism[147]. Although age at onset for PINK1related PD is usually in the
fourth to fifth decade, clinical features are similar to late onset PD, with slow progression,
excellentresponsetoLDOPA,andinsomecases,dementia[238241].Nigrostriatalneuronal
losshasbeenobservedinpostmortembrainsofPDpatientswithPINK1mutations[242].
PINK1 is a putative serine/threonine kinase, constituted by 581 amino acids, which is
expressed ubiquitously. Until present, homozygous missense and nonsense mutations
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ofPINK1 function inhumancell linesoriginatedmorphological changesofmitochondriaand
impaired energy metabolism, showed by a decreased mitochondrial membrane potential
[243].CellsisolatedfromindividualswithaPINK1mutationthatcausesaG309Dsubstitution
demonstrate reduced complex I activity and evidence of increased oxidative damage
compared with cells from age matched controls [246]. Furthermore, PINK1 deficiency in a
Drosophilamodelresultsinthelossofdopaminergiccells,aswellasincreasedsusceptibilityto
oxidative stress and reduced ATP levels [247]. These mutants also showed reduced
mitochondrial mass with disorganized morphology. Moreover, PINK1 seems to exert
neuroprotective properties, as shown by Petit et al.(2005)[248]where WT, but not mutant
PINK1attenuatedstaurosporineinducedapoptosisandreducedmitochondrial cytochromec
releasewhenoverexpressedinSHSY5Ycells.Also,silencingofPINK1increasedsusceptibility






was suggested that the two proteins could act in common pathways, with parkin working
downstreamof PINK1, since transgenic expression of parkin rescued all PINK1 impairments,
but not the contrary [243, 250, 251]. Goldman et al.(2010)[252], described that PINK1 and
parkinbothdisplayaroleinthemitochondrialtargetingofautophagy,aprocessbywhichthe
cellsdegradeintracellularmaterialthroughlysosomes.Mitophagy,whichisthemitochondrial
specific form of this process, is important in the control of damaged or stressed cellular




with lowmembranepotential,where itmediates thedegradationof the impairedorganelle
[254]. PINK1 works as the biochemical signal which allows parkin to identify dysfunctional
mitochondria, whose levels are regulated by voltagedependent proteolysis [255]. The E3
ligasefunctionofparkin,whichisconstitutivelyinhibited,isactivateduponPINK1dependent
mitochondrial localization [256]. Therefore, defective mitophagy due to a lack of parkin
recruitment to impaired mitochondria by PINK1 causes the accumulation of dysfunctional
mitochondria and a subsequent enhanced ROS levels and proapoptotic proteins [257]. In
addition, overexpression of PINK1 promotes mitochondrial fission, while inhibition of the
protein causes an excessive fusion [258, 259]. Fibroblasts from PD patients carrying
homozygous PINK1 mutations had truncated mitochondria networks compared to control
fibroblasts, when cultured in mediumwith low glucose, or in the presence of galactose to
favor mitochondrial energy metabolism over glycolysis [243, 260]. Moreover, in fibroblasts






pathway may indeed change the balance of mitochondrial dynamics towards fission under
basalconditions,butfavorahigherdegreeoffunctionalconnectivityoftheorganellesunder
conditionsofenergydepletionorhighenergydemand.Interestingly,mitochondrialbranching
wasmore evident aftermitochondrial complex I inhibition in control fibroblasts,whichmay
indicate that increasing mitochondrial connectivity may represent a protective response of
cellstoanenergycrisis[261].
Piccoliandcolleagues[262]alsoperformedstudiesonfibroblasts fromapatientwithaPINK1
mutationandobserveda lowmitochondrial respiratoryactivityand increasedoxygenradical
production due to complex I inhibition, demonstrating clinically what has been shown
experimentally.
DJ1
Mutations in DJ1 gene, also known as PARK7, are the least common cause of autosomal
recessive PD (approximately 1% of earlyonset PD). TheDJ1related phenotype,with early
onset and slow disease progression, closely matches that of patients with parkin or PINK1
mutations,butgenotype/phenotypecorrelationscouldnotbepreciselyperformed,duetothe











insults and reduced intracellular ROS formation [272]. This protection seems tobe selective
againstenvironmentaloxidative stress invivo,as shown inDJ1nullDrosophila treatedwith
paraquatandrotenone[273].Thus,DJ1deficientfliesdisplayedalocomotordeficitthatwas
exacerbated by oxidative stress [274].Furthermore, the levels of DJ1 modification increase
withage,alsoleadingtosignificant incrementsinoxidativestressandinactivationof itsown
function [275]. DJ1deficient mice demonstrated hypersensitivity to MPTP and this was
observed by increased dopaminergic neuronal loss and striatal denervation [276]. In
embryonic cortical neurons, an increased sensitivity to oxidative stress and proteasomal
inhibitionhas been also demonstrated, ending in apoptotic cell death [276, 277]. All
impairmentswerereversedbyrestitutionofDJ1expression.DJ1isnormallyactivatedbyan
oxidativecytoplasmicenvironment [278]. Shendelmanandcolleagues(2004)describedarole
for DJ1 as a redoxsensitive molecular chaperone, which was able to inhibit alphasyn
aggregateformation.AnotherstudyinDJ1deficientmiceshowedthatthecomplexIinhibitor
paraquat decreased proteasome activity concomitantly with decreased ATP and regulatory
subunit levels[279]. In addition to these effects, the levels of a transcription factor [nuclear
factorerythroid2relatedfactor2(Nrf2)],whichactivatescytoprotectivegenes,werereduced.
This providedevidence for a role ofDJ1 as a regulator of transcription. Themechanismby
which DJ1 protects against oxidative stress was described by Im et al.(2010)[280]. In this
study, the authors demonstrated that DJ1 regulates the MAP3 kinase apoptosis signaling
regulatingkinase1(ASK1)/thioredoxin1(Trx1)complex.ASK1isamajoreffectorofcelldeath





al.(2009)[281], who showed DJ1 binding to NADH dehydrogenase (ubiquinone) 1 
subcomplex4(NDUFA4)andtomitochondrialencodedNADHdehydrogenase1(ND1),nuclear
and mitochondrial DNAencoding subunits of complex I, respectively, validating the
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importance of DJ1 in mitochondrial function. Recently, a direct link between loss of DJ1,
impairedmitochondrialstressresponseandreducedclearanceofmitochondriaby lysosomal
degradation was described [282]. An accumulation of fragmented and dysfunctional
mitochondriauponreducedbasalautophagycontributedtothelossoffunctionphenotypein
cellsfromDJ1knockoutmouseandhumancarriersoftheE64DmutationinDJ1gene[282].
In summary, PD individualswithautosomal recessive inheritancediffergenerally from those
withidiopathicPD,althoughcaseswithclinicalevolutionsimilartothatofthetypicaldisease
havebeenreported.Araisingbodyofrecentinformation,providesstrongsupporttotheidea
that mitochondrial dysfunction may be central to the pathophysiology of familial PD,
particularly to that of parkinsonian syndromes with autosomal recessive inheritance that
directlyassociatewithmitochondria,suchasparkin,PINK1andDJ1.
PsychostimulantdrugsofabuseandPD
Psychostimulant drugs of abuse are psychoactive drugs which induce temporary
improvements inmental and/or physical function, such as enhanced alertness,wakefulness
andlocomotion.Thesedrugsincreasetheextracellularconcentrationofmonoamines,suchas
dopamine, leading to increased dopamine transmission [283]. Dopamine is involved in




amphetamineswas suggested to affect the progression of PD, sinceincreased risk of PDwas




Similarly toPD, theneurotoxicityobserveduponexposure to amphetaminesmaybedue to
dopamineinduced oxidative stress. Amphetamines increase extraneuronal dopamine and
other monoamine levels, through a nonexocytotic mechanism, by directly interacting with




and leading to an increase in extracellular dopamine [289]. When present in higher
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extracellular concentrations, amphetamine may diffuse into the cell, due to its lipophilicity
[290,291].AmphetaminealsointerfereswithVMAT2function,impairingtheactivetransport
of themonoamines into synaptic vesicles,where theyare stored. In addition, amphetamine
mayenterinthevesiclesbydiffusion,duetoitsweakbaseproperties[292,forreview].Since
amphetamineisaweakbase,atacidicpHitacceptsprotonsleadingtoalkalinizationinsidethe
vesicles. A low pH inside the vesicles is essential to maintain the proton gradient used by
VMAT2 for active transport of monoamines into the vesicles. Therefore, amphetamine
inducesthereleaseofvesiculardopaminetothecytosolandimpairsthestorageofdopamine
in the vesicles. Cytosolic dopamine is then released to the extracellular space via reverse
transportbytheDAT.Amphetaminealsointerfereswithdopaminemetabolismbyinhibiting
MAO[293], andwith dopamine synthesis, by inhibiting TH[294].Thus, longtermexposure to
amphetamine leads to dopamine depletion [295], and reduction in dopaminergic markers
[296].
Amphetamineshavebeenshownto inducecommonfeaturesofPD.Asignificantassociation
between variations in a highly polymorphic sequence (T10A7) of the alphasyn gene and




amphetamines were previously described to induce neuronal inclusions and affect proteins
belonging to the UPS, in the central nervous system [298]; moreover,ultrastructural and
molecular changes were similar to those occurring in PD [299]. Amphetamineinduced
neuronalinclusionspresentmanyfeaturessimilartothoseobservedinPD,andthematuration
of these inclusions can be reproduced by continuous exposure to parkinsonian neurotoxins
suchasrotenone[84,300]orMPTP[301].Inmice,occurrenceofneuronalinclusionscombined
with increasednigralexpressionofalphasynwithindopaminergicneuronswerefoundupon
treatment with amphetamine derivatives[302], similarly to what occurs following
administration of the parkinsonian toxinMPTP [303]. Furthermore, treatment ofmicewith
methamphetamine increased markers of oxidative stress in the striatum and increased the
levels of oligomeric alphasyn in the SN[304]. In this context, increasedalphasyn expression
followingmethamphetaminemaybeaprotectivemechanism,sincealphasynfibrilssequester
thetoxicspecies formedupon intracellulardopamineoxidation,preventing furtheroxidative
damage[128].
Exposure to amphetamine or amphetamine derivatives has been shown to induce oxidative
stress in thenervous system [305, 306].Methamphetamine andDamphetaminehavebeen
26

shown to increase ROS levels upon in vitro[307, 308] or in vivo[309, 310] exposure and the
toxic effects of these drugs may be prevented by antioxidants. Moreover, in
methamphetaminehumanabuserstheactivityofantioxidantenzymeswasaffectedinseveral
regions of the brain [311]. In animalmodels,methamphetamine [312] and Damphetamine
[313,314]alsoaffectedtheactivityofantioxidantenzymes.Inaddition,evidencesofoxidative
damage have been reported in the brains of metamphetamine human abusers [315] and
methamphetamine[312]orDamphetamine[309]exposedanimals.
InPC12catecholaminergiccellcultures,wehavepreviouslyshownthatprolongedexposureto
low (nontoxic) concentrationsofDamphetamine induces a partial protection againstH2O2
induced toxicity, which was suggested to be associated with adaptation to oxidative stress
[316]. Other authors showed that a shortterm exposure to subtoxic concentrations of
methamphetamine can protect dopaminergic cells against a larger oxidative stress injury,
throughupregulationofBcl2[317].




Cardinal cellular features of idiopathic PD are classically linked tomitochondrial dysfunction
andoxidativestress,whichhasastrongbasisbothonmitochondrialcomplexI inhibitionand
dopamineautoxidation.Interestingly,alphasyn,aproteinpresentinLBsandwhichexpression
and mutations cause one of the familial autosomal dominant forms of PD, promotes ROS
formationand interactswithdopaminequinones.On theotherhand, LRRK2mutations have
been linked to late onset cases of PD (resembling sporadic forms),leading to altered
mitochondrial function and alphasyn aggregation. Evidences for mitochondrial dysfunction
andoxidativestressarealsoverycleartodayinsomeautosomalrecessivefamilialformsofPD
caused by mutations in parkin, PINK1 and DJ1, which directly associate and regulate
mitochondrialfunction,dynamicsanddegradation.
Interestingly,abuseofpsychostimulants,namelyamphetamines,havebeenlargelydescribed
toaffectdopaminergic transmissionand function,and inducedopaminedepletion.Although
thesedrugsmaynotdirectlyevokePD, theymaypredispose thecentralnervoussystem for
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regions: the amphipatic region in the Nterminal, a central hydrophobic NAC (non amyloid
component) domain and an acidic Cterminal region. The three pathogenic missense
mutationsarerepresentedinred.Numbersabovetheproteinlineindicatethelimitsofeach
region.
Figure 2 – Schematic representation of the LRRK2 protein. LRRK2 is a 2527 amino acid
protein, constituted by several conserved domains: ARM (Armadillo), ANK (ankyrin repeat),
LRR (leucinerich repeat), Roc (Ras of complex proteins: GTPase), COR (Cterminal of Roc),





neurons contain Fe2+ and neuromelanin, which results from dopamine (DA) oxidation, in a
process that generates dopamine quinone (DAQ) and reactive oxygen species (ROS).
Neuromelaninmayalsobeprotective,sinceitbindsFe2+,knowntopromotetheformationof
thehighlytoxichydroxyl(.OH)radicalbytheFentonreaction.2)FamilialPDmaybecausedby
duplication/triplicationofalphasynuclein (syn)orbymutations in thisandotherproteins,
suchas LRRK2,DJ1, ParkinandPINK1,whichmay induceoxidative stressby gainor lossof
function.WildtypeDJ1andParkinhaveantioxidanteffectsthatarelostwiththepathogenic
mutations. 3) A common characteristic of different forms of PD is the occurrence of syn
aggregationandthepresenceofsyncontainingLewybodies(LB)andLewyneurites(LN).4)
Impairment of energy metabolism in PD, resulting from mitochondrial dysfunction, may
increase glutamate release, exacerbatingNmethylDaspartate (NMDA) receptor activation.
This leads to an increase in intracellular Ca2+, which activates neuronal nitric oxide (.NO)
synthase (nNOS), leading to the formation of NO.,which readily reactswith the superoxide
anion (O2
.), forming the highly toxic peroxynitrite (ONOO). B. 5) PD phenotype may be
recreated by a number of mitochondrial toxins. MPTP is converted into MPP+ by glial
monoamine oxidases (MAOB) and this metabolite may be transported by the dopamine
transporter (DAT) into the DA nerve terminals, where it inhibits mitochondrial electron




induces PDsimilar phenotype by inhibitingmitochondrial complex I. 6) Amphetamine drugs
directly affect DAergic nerve terminals, reproducing most of PD molecular hallmarks.
Amphetamine (AMPH) is taken up by the DAT and impairs the active transport of DA into
synapticvesicles,leadingtoanincreaseincytosolicDA,whichismetabolizedbyMAO,leading
toH2O2 formation,orbyautoxidation,with the generationofDAQ,O2
. andH2O2.DAQmay
react with syn, stabilizing syn protofibrils and promoting syn aggregation. This may
preventDAQfromproducinggreateroxidativedamageinDAergicneurons.CytosolicDAmay
also be released to the extracellular space via reversetransport by the DAT. AMPH also
interfereswithDAmetabolism,byinhibitingMAO,andwithDAsynthesis,byinhibitingtyrosine
hydroxylase(TH),whichcanleadtodopaminedepletionafterprolongedexposuretothisdrug.
AMPH also inducesmitochondrial dysfunction involving a loss ofmitochondrial potential. 7)
MutantPink1mayalsoinhibitmitochondrialcomplexI.
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